{"ATC Code":"N07AA01","Abbreviation":"","Aliases":["Eustigmin","Eustigmine","Vagostigmine","Prostigmin","Juvastigmin","Neostigmin","Neostigminum","Intrastigmina","m-Trimethylammoniumphenyldimethylcarbamate","3-Trimethylammoniumphenyl N,N-dimethylcarbamate"],"Biological Half-Life":"The half-life ranged from 42 to 60 minutes with a mean half-life of 52 minutes.","CAS":"59-99-4","ChEBI":"CHEBI:7514","ChEMBL":"CHEMBL278020","ChemicalClasses":[],"Chirality":"achiral","Classes":null,"Dosing Info":[],"Drug Classes":"Breast Feeding; Lactation; Cholinesterase Inhibitors; Parasympathomimetics","Drug Indication":"Neostigmine is used for the symptomatic treatment of myasthenia gravis by improving muscle tone.","Drug Warnings":"...NEOSTIGMINE, MUST BE USED CAUTIOUSLY IN PATIENTS WITH CARDIAC DYSRHYTHMIAS OR BRONCHIAL ASTHMA.","DrugClasses":[],"DurationOfAction":"up to 4 hrs","EliminationHalfLife":"50–90 minutes","FDA Pharmacological Classification":"3982TWQ96G","FullSalts":["Neostigmine mesylate"],"HMDB ID":"HMDB0015472","HeavyAtomCount":16,"Human Drugs":"Breast Feeding; Lactation; Cholinesterase Inhibitors; Parasympathomimetics","IUPACName":"[3-(dimethylcarbamoyloxy)phenyl]-trimethylazanium","InChI":"InChI=1S/C12H19N2O2/c1-13(2)12(15)16-11-8-6-7-10(9-11)14(3,4)5/h6-9H,1-5H3/q+1","InChIKey":"ALWKGYPQUAPLQC-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. (See all compounds classified as Cholinesterase Inhibitors.)","MolecularFormula":"C\u003csub\u003e12\u003c/sub\u003eH\u003csub\u003e19\u003c/sub\u003eN\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e2\u003c/sub\u003e+","MolecularWeight":"223.29 g/mol","Pharmacodynamics":"Neostigmine is a cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier. By inhibiting acetylcholinesterase, more acetylcholine is available in the synapse, therefore, more of it can bind to the fewer receptors present in myasthenia gravis and can better trigger muscular contraction.","Physical Description":"Solid","PrevSalts":["mesylate"],"PubChemId":4456,"Record Description":["Neostigmine is a quaternary ammonium ion comprising an anilinium ion core having three methyl substituents on the aniline nitrogen, and a 3-[(dimethylcarbamoyl)oxy] substituent at position 3. It is a parasympathomimetic which acts as a reversible acetylcholinesterase inhibitor. It has a role as an EC 3.1.1.7 (acetylcholinesterase) inhibitor and an antidote to curare poisoning.","A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier.","Neostigmine is a Cholinesterase Inhibitor. The mechanism of action of neostigmine is as a Cholinesterase Inhibitor.","Neostigmine is a parasympathomimetic agent that acts as a reversible acetylcholinesterase inhibitor.","NEOSTIGMINE is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for myasthenia gravis and glaucoma and has 10 investigational indications.","A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.","See also: Neostigmine Methylsulfate (has salt form); Neostigmine Bromide (has salt form); Neostigmine hydroxide (is active moiety of).","Neostigmine is a quaternary ammonium ion comprising an anilinium ion core having three methyl substituents on the aniline nitrogen, and a 3-[(dimethylcarbamoyl)oxy] substituent at position 3. It is a parasympathomimetic which acts as a reversible acetylcholinesterase inhibitor. It has a role as an EC 3.1.1.7 (acetylcholinesterase) inhibitor and an antidote to curare poisoning.","LiverTox|CNS|Muscle stimulant|Cholinesterase inhibitor"],"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Neostigmine","Name":"Neostigmine","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q410546","Name":"Neostigmine","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB01400","Name":"Neostigmine","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/4456","Name":"Neostigmine","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL278020","Name":"Neostigmine","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:7514","Name":"Neostigmine","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=59-99-4","Name":"Neostigmine","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0015472","Name":"Neostigmine","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C07258","Name":"Neostigmine","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/3982TWQ96G","Name":"Neostigmine","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023360","Name":"Neostigmine","Sub":false}]}],"SMILES":"CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C","Salts":["mesylate"],"SaltsAcidCount":[0],"SaltsAmineCount":[1],"SaltsUNII":["6F5UW4E5CF"],"Scheduling":[{"gov":"Australia","schedule":"S4 substance"},{"gov":"United Kingdom","schedule":"prescription only substance"},{"gov":"United States","schedule":"prescription only substance"}],"Solubility":"6.77e-02 g/L","StoreUNII":["3982TWQ96G"],"StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="64.96mm" version="1.2" viewBox="0 0 71.76 64.96" width="71.76mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#3050F8" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="65.0" stroke="none" width="72.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="68.941" x2="58.896" y1="33.561" y2="27.762"/>
                  
            <line class="bond" id="mol1bnd2" x1="52.589" x2="42.544" y1="27.762" y2="33.561"/>
                  
            <line class="bond" id="mol1bnd3" x1="55.742" x2="55.742" y1="22.091" y2="10.701"/>
                  
            <g class="bond" id="mol1bnd4">
                        
                <line x1="54.523" x2="65.05" y1="9.997" y2="3.92"/>
                        
                <line x1="55.742" x2="66.269" y1="12.109" y2="6.031"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="65.05" x2="59.786500000000004" y1="3.92" y2="6.9585"/>
                <line class="hi" stroke="#FF0D0D" x1="66.269" x2="61.0055" y1="6.031" y2="9.07"/>
            </g>
                  
            <line class="bond" id="mol1bnd5" x1="55.742" x2="45.82" y1="10.701" y2="4.972"/>
                  
            <line class="bond" id="mol1bnd6" x1="39.263" x2="29.346" y1="4.975" y2="10.701"/>
                  
            <g class="bond" id="mol1bnd7">
                        
                <line x1="29.346" x2="16.143" y1="10.701" y2="3.073"/>
                        
                <line x1="26.908" x2="16.142" y1="12.109" y2="5.889"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd8" x1="16.143" x2="2.945" y1="3.073" y2="10.693"/>
                  
            <g class="bond" id="mol1bnd9">
                        
                <line x1="2.945" x2="2.949" y1="10.693" y2="25.941"/>
                        
                <line x1="5.383" x2="5.387" y1="12.1" y2="24.534"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd10" x1="2.949" x2="16.153" y1="25.941" y2="33.57"/>
                  
            <g class="bond" id="mol1bnd11">
                        
                <line x1="16.153" x2="29.351" y1="33.57" y2="25.95"/>
                        
                <line x1="16.153" x2="26.912" y1="30.754" y2="24.542"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd12" x1="29.346" x2="29.351" y1="10.701" y2="25.95"/>
                  
            <line class="bond" id="mol1bnd13" x1="16.153" x2="16.151" y1="33.57" y2="44.593"/>
                  
            <line class="bond" id="mol1bnd14" x1="20.777" x2="31.39" y1="48.81" y2="48.812"/>
                  
            <line class="bond" id="mol1bnd15" x1="16.149" x2="16.148" y1="52.659" y2="64.05"/>
                  
            <line class="bond" id="mol1bnd16" x1="12.809" x2=".91" y1="48.809" y2="48.807"/>
                  
            <path class="atom" d="M57.683 28.391h-.72l-2.62 -4.066h-.029q.011 .238 .029 .595q.024 .357 .024 .732v2.739h-.565v-4.9h.714l2.607 4.055h.03q-.006 -.108 -.018 -.328q-.012 -.22 -.023 -.476q-.006 -.262 -.006 -.482v-2.769h.577v4.9z" id="mol1atm2" stroke="none"/>
                  
            <path class="atom" d="M71.2 3.078q-.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.244 .315q-.757 .0 -1.263 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q.0 -.75 .244 -1.309q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.733 .0 1.233 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM67.336 3.078q.0 .923 .387 1.459q.393 .53 1.221 .53q.839 -.0 1.22 -.53q.387 -.536 .387 -1.459q-.0 -.929 -.387 -1.452q-.381 -.524 -1.209 -.524q-.833 -.0 -1.226 .524q-.393 .523 -.393 1.452z" fill="#FF0D0D" id="mol1atm5" stroke="none"/>
                  
            <path class="atom" d="M44.803 3.078q.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q-.0 -.75 .244 -1.309q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.732 .0 1.232 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM40.94 3.078q-.0 .923 .387 1.459q.393 .53 1.22 .53q.839 -.0 1.22 -.53q.387 -.536 .387 -1.459q.0 -.929 -.387 -1.452q-.381 -.524 -1.208 -.524q-.833 -.0 -1.226 .524q-.393 .523 -.393 1.452z" fill="#FF0D0D" id="mol1atm6" stroke="none"/>
                  
            <g class="atom" id="mol1atm13">
                        
                <path d="M18.091 51.259h-.721l-2.619 -4.066h-.03q.012 .238 .03 .596q.024 .357 .024 .732v2.738h-.566v-4.899h.715l2.607 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.221 -.024 -.477q-.006 -.262 -.006 -.482v-2.768h.578v4.899z" stroke="none"/>
                        
                <path d="M19.767 46.215h.818v.293h-.818v.847h-.297v-.847h-.818v-.293h.818v-.85h.297v.85z" stroke="none"/>
                      
            </g>
                
            <line class="hi" id="mol1bnd1" stroke="#3050F8" x1="58.896" x2="63.9185" y1="27.762" y2="30.6615"/>
            <line class="hi" id="mol1bnd2" stroke="#3050F8" x1="52.589" x2="47.5665" y1="27.762" y2="30.6615"/>
            <line class="hi" id="mol1bnd3" stroke="#3050F8" x1="55.742" x2="55.742" y1="22.091" y2="16.396"/>
            <line class="hi" id="mol1bnd5" stroke="#FF0D0D" x1="45.82" x2="50.781" y1="4.972" y2="7.836500000000001"/>
            <line class="hi" id="mol1bnd6" stroke="#FF0D0D" x1="39.263" x2="34.3045" y1="4.975" y2="7.838"/>
            <line class="hi" id="mol1bnd13" stroke="#3050F8" x1="16.151" x2="16.152" y1="44.593" y2="39.081500000000005"/>
            <line class="hi" id="mol1bnd13" stroke="#3050F8" x1="16.151" x2="16.152" y1="44.593" y2="39.081500000000005"/>
            <line class="hi" id="mol1bnd14" stroke="#3050F8" x1="20.777" x2="26.0835" y1="48.81" y2="48.811"/>
            <line class="hi" id="mol1bnd14" stroke="#3050F8" x1="20.777" x2="26.0835" y1="48.81" y2="48.811"/>
            <line class="hi" id="mol1bnd15" stroke="#3050F8" x1="16.149" x2="16.1485" y1="52.659" y2="58.3545"/>
            <line class="hi" id="mol1bnd15" stroke="#3050F8" x1="16.149" x2="16.1485" y1="52.659" y2="58.3545"/>
            <line class="hi" id="mol1bnd16" stroke="#3050F8" x1="12.809" x2="6.8595" y1="48.809" y2="48.808"/>
            <line class="hi" id="mol1bnd16" stroke="#3050F8" x1="12.809" x2="6.8595" y1="48.809" y2="48.808"/>
        </g>
          
    </g>
    
</svg>
","Therapeutic Uses":"Cholinesterase Inhibitors; Parasympathomimetics","Title":"Neostigmine","UNII":"3982TWQ96G","Wikidata":"Q410546","Wikipedia":"Neostigmine","XLogP":1.5}